For example, the most common mechanism of acquired resistance to EGFR-TKIs in NSCLC is the development of a secondary T790M mutation within the EGFR gene, which impairs the drug’s binding affinity to the receptor, thereby reducing the effectiveness of EGFR-TKI therapy [27]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.